RGEN
NASDAQRepligen Corporation
Price$117.26+1.15 (+0.99%)
01:30 PM07:45 PM
News · 26 weeks44-14%
2025-11-022026-04-26
Mix2890d
- Insider13(46%)
- SEC Filings6(21%)
- Other5(18%)
- Earnings3(11%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form DEFA14A filed by Repligen CorporationDEFA14A - REPLIGEN CORP (0000730272) (Filer)
- INSIDERSEC Form 4 filed by Loeillot Olivier4 - REPLIGEN CORP (0000730272) (Issuer)
- PRRepligen to Report First Quarter 2026 Financial ResultsWALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended March 31, 2026. The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 931163466. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. The w
- SECSEC Form 144 filed by Repligen Corporation144 - REPLIGEN CORP (0000730272) (Subject)
- ANALYSTRothschild & Co Redburn initiated coverage on Repligen with a new price targetRothschild & Co Redburn initiated coverage of Repligen with a rating of Buy and set a new price target of $160.00
- PRRepligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support NetworkWALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new Repligen Training & Innovation Center ("RTIC") at its OPUS® Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands. The RTIC buildout, which features product exhibits and purpose-built demonstration areas, was designed to provide customers with pre- and post-sales support, and a hands-on experience with Repligen's innovative bioprocessing solutions. The Breda RTIC is Repligen's third global training and innovation center, joining existing locations in Waltham,
- SECSEC Form DEFA14A filed by Repligen CorporationDEFA14A - REPLIGEN CORP (0000730272) (Filer)
- SECSEC Form DEF 14A filed by Repligen CorporationDEF 14A - REPLIGEN CORP (0000730272) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Repligen CorporationSCHEDULE 13G/A - REPLIGEN CORP (0000730272) (Subject)
- INSIDERSEC Form 4 filed by Kuriyel Ralf4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERSEC Form 4 filed by Loeillot Olivier4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERSEC Form 4 filed by Bylund James4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERSEC Form 4 filed by Garland Jason K4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERChief Operating Officer Bylund James was granted 125 shares and covered exercise/tax liability with 62 shares, increasing direct ownership by 0.36% to 17,672 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERSenior VP, R&D Kuriyel Ralf was granted 125 shares and covered exercise/tax liability with 42 shares, increasing direct ownership by 0.56% to 14,778 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- PRRepligen Corporation to Present at Upcoming March ConferencesWALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating in three upcoming investor conferences. The Leerink Global Healthcare Conference, being held March 8 – 11 in Miami. Jason Garland, Chief Financial Officer, will participate in an analyst led discussion at 11:20 a.m. ET on Tuesday, March 10, 2026.The Barclays 28th Annual Global Healthcare Conference, being held March 10 – 12 in Miami. Jason Garland, Chief Financial Officer, will participate in an analyst led discussion at 10:30 a.m. ET on Wednesday, March 11, 2026.The 2026 KeyBanc Virtual
- INSIDERChief Operating Officer Bylund James covered exercise/tax liability with 3,911 shares, decreasing direct ownership by 18% to 17,609 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERChief Executive Officer Loeillot Olivier covered exercise/tax liability with 1,954 shares, decreasing direct ownership by 5% to 33,944 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Hunt Anthony covered exercise/tax liability with 9,897 shares, decreasing direct ownership by 10% to 89,062 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERCFO Garland Jason K covered exercise/tax liability with 1,042 shares, decreasing direct ownership by 8% to 12,341 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERSenior VP, R&D Kuriyel Ralf covered exercise/tax liability with 1,367 shares, decreasing direct ownership by 9% to 14,695 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERCHIEF PRODUCT OFFICER Douglass Brian Robb covered exercise/tax liability with 221 shares, decreasing direct ownership by 3% to 8,319 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- SECSEC Form 10-K filed by Repligen Corporation10-K - REPLIGEN CORP (0000730272) (Filer)
- SECRepligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REPLIGEN CORP (0000730272) (Filer)
- PRRepligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial GuidanceFourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVIDFull year 2026 revenue guidance of $810 million - $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpoint WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2025, covering the three- and twelve-
RGEN FAQ
7 questionsWhat does Repligen Corporation do?
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance...Where does RGEN stock trade?
Repligen Corporation (RGEN) is listed on NASDAQ.What sector and industry is RGEN in?
Repligen Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Repligen Corporation go public?
Repligen Corporation (RGEN) completed its IPO in 1986.What are analysts saying about RGEN?
Repligen Corporation has had 8 recent analyst actions on file. The most recent action was from Rothschild & Co Redburn: Buy on 2026-04-17.What companies are similar to RGEN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare RGEN side-by-side with any of them on Quantisnow.How can I track RGEN on Quantisnow?
Quantisnow aggregates Repligen Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGEN to receive live email and push alerts on every new disclosure.